Skip to main content
Year archive

BioLineRx Ltd. — 2025 filings

All 52 regulatory filings released by BioLineRx Ltd. (BLRX) in 2025, sourced directly from the official regulator.

52 Filings
2025 Period
2025 filings (52)
Filing Released Lang
Third Quarter 2025 Financial Results and Provides Corporate Update
Interim / Quarterly Report 9M 2025
2025-11-24 English
Third Quarter 2025 Financial Results and Provides Corporate Update
Report Publication Announcement
2025-11-24 English
6-K
Foreign Filer Report
2025-11-24 English
6-K
Foreign Filer Report
2025-11-17 English
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Regulatory Filings
2025-11-17 English
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Regulatory Filings
2025-11-17 English
6-K
Foreign Filer Report
2025-09-29 English
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
Regulatory Filings
2025-09-29 English
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
Regulatory Filings
2025-09-29 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
6-K
Foreign Filer Report
2025-08-14 English
Second Quarter 2025 Financial Results and Provides Corporate Update
Earnings Release Q2 2025
2025-08-14 English
Second Quarter 2025 Financial Results and Provides Corporate Update
Report Publication Announcement
2025-08-14 English
Immediate Report
Capital/Financing Update
2025-07-26 English
Immediate Report
Capital/Financing Update
2025-07-26 English
424B5
Prospectus
2025-07-25 English
Immediate Report
AGM Information
2025-06-30 English
Immediate Report
AGM Information
2025-06-30 English
6-K
Foreign Filer Report
2025-06-30 English
New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
Regulatory Filings
2025-05-30 English
New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
Report Publication Announcement
2025-05-30 English
6-K
Foreign Filer Report
2025-05-30 English
6-K
Foreign Filer Report
2025-05-27 English
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
Interim / Quarterly Report Q1 2025
2025-05-27 English
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
Earnings Release Q1 2025
2025-05-27 English
Immediate Report of Meeting to be held on June 29,2025,proxy statement
Proxy Solicitation & Information Statement
2025-05-24 English
Immediate Report of Meeting to be held on June 29,2025,proxy statement
AGM Information
2025-05-24 English
Immediate Report of Meeting to be held on June 29,2025,proxy statement
AGM Information
2025-05-24 English
6-K
Foreign Filer Report
2025-05-23 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update
2025-04-14 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update
2025-04-14 English
424B5
Prospectus
2025-04-11 English
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
Annual Report FY 2024
2025-03-31 English
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
Earnings Release FY 2024
2025-03-31 English
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
Earnings Release FY 2024
2025-03-31 English
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
Report Publication Announcement FY 2024
2025-03-31 English
6-K
Foreign Filer Report
2025-03-31 English
20-F
Annual Report FY 2024
2025-03-31 English
Letter to Shareholders
Management Reports
2025-01-21 English
Letter to Shareholders
Report Publication Announcement
2025-01-21 English
6-K
Foreign Filer Report
2025-01-21 English
Change to Ratio of American Depositary Shares to Ordinary Shares from 15 ordinary shares per ADS to 600 ordinary shares per ADS, will be effective on January 30, 2025
Regulatory Filings
2025-01-18 English
Change to Ratio of American Depositary Shares to Ordinary Shares from 15 ordinary shares per ADS to 600 ordinary shares per ADS, will be effective on January 30, 2025
Report Publication Announcement
2025-01-18 English
6-K
Foreign Filer Report
2025-01-17 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-01-11 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update
2025-01-07 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update
2025-01-07 English
6-K
Foreign Filer Report
2025-01-07 English
424B5
Prospectus
2025-01-07 English
BioLineRx Announces $10 Million Registered Direct Offering
Capital/Financing Update
2025-01-06 English
BioLineRx Announces $10 Million Registered Direct Offering
Report Publication Announcement
2025-01-06 English
6-K
Foreign Filer Report
2025-01-06 English